ADC Therapeutics SA (ADCT)
1.32
-0.03 (-2.22%)
At close: Apr 02, 2025, 10:01 AM
-2.22% (1D)
| Bid | 1.32 |
| Market Cap | 131.29M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.62 |
| PE Ratio (ttm) | -0.82 |
| Forward PE | -1.15 |
| Analyst | Buy |
| Ask | 1.33 |
| Volume | 33,232 |
| Avg. Volume (20D) | 447,723 |
| Open | 1.34 |
| Previous Close | 1.35 |
| Day's Range | 1.30 - 1.34 |
| 52-Week Range | 1.28 - 5.38 |
| Beta | 1.52 |
About ADCT
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second...
Industry Biotechnology
Sector Healthcare
IPO Date May 18, 2020
Employees 263
Stock Exchange NYSE
Ticker Symbol ADCT
Website https://www.adctherapeutics.com
Analyst Forecast
According to 5 analyst ratings, the average rating for ADCT stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 503.77% from the latest price.
Stock ForecastsEarnings Surprise
ADC Therapeutics SA has released their quartely earnings
on Mar 27, 2025:
Next Earnings Release
ADC Therapeutics SA is scheduled to release its earnings on May 5, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+63.02%
ADC Therapeutics shares are trading higher after t...
Unlock content with
Pro Subscription
